
Please try another search
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases. The company develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. Wuhan YZY Biopharma Co., Ltd. was founded in 2010 and is headquartered in Wuhan, China.
Name | Age | Since | Title |
---|---|---|---|
Ying Xiao | 35 | 2023 | Employee Representative Supervisor |
Pengfei Zhou | 57 | 2014 | Chairman of the Board & CEO |
Changtao Ji | 35 | 2021 | Supervisor |
Fang Liu | 46 | 2016 | Supervisor |
Qian Liang | 51 | 2018 | Non-Executive Director |
Qian Yuan | 57 | 2010 | Non-Executive Director |
Jing Zhang | 41 | 2018 | Senior Director of the R&D Center and Supervisor |
Xiwu Hui | 39 | 2022 | Non-Executive Director |
Bin Chen | 62 | 2022 | Independent Non-Executive Director |
Hongfeng Zhou | 54 | 2010 | Non-Executive Director |
Jumin Sun | 48 | 2018 | Chairman of the Supervisory Committee |
Lili Fu | 39 | 2022 | Independent Non-Executive Director |
Bin Cheng | 57 | 2022 | Independent Non-Executive Director |
Yuezhen Deng | 44 | 2022 | Independent Non-Executive Director |
Shouwu Xie | 40 | 2022 | Non-Executive Director |
Junming Wang | - | 2025 | Shareholder Representative Supervisor |
Zhenhai Pang | 49 | 2020 | Non-Executive Director |
Zhicheng Wen | 43 | 2024 | Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review